



Clinical trial results: Prevention of Aortic Stenosis Pilot Trial Summary

EudraCT number	2015-000704-25
Trial protocol	GB
Global end of trial date	11 December 2018

Results information

Result version number	v1 (current)
This version publication date	18 December 2019
First version publication date	18 December 2019
Summary attachment (see zip file)	Study paper (PASPilotTrialpdf.pdf)

Trial information

Trial identification

Sponsor protocol code	PASP01
-----------------------	--------

Additional study identifiers

ISRCTN number	ISRCTN17365679
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-
Other trial identifiers	N/A: N/A

Notes:

Sponsors

Sponsor organisation name	Queen Mary University of London
Sponsor organisation address	5 Walden Street, London, United Kingdom, E1 2EF
Public contact	David Wald, Queen Mary University of London, 0044 02078826298, d.s.wald@qmul.ac.uk
Scientific contact	David Wald, Queen Mary University of London, 0044 02078826298, d.s.wald@qmul.ac.uk
Sponsor organisation name	Queen Mary University of London
Sponsor organisation address	5 Walden Street, London, United Kingdom, E1 2EF
Public contact	Prof D Wald, Queen Mary University of London, 0044 207 882 7279, d.s.wald@qmul.ac.uk
Scientific contact	Prof D Wald, Queen Mary University of London, 0044 207 882 7279, d.s.wald@qmul.ac.uk

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	02 July 2019
Is this the analysis of the primary completion data?	Yes
Primary completion date	11 December 2018
Global end of trial reached?	Yes
Global end of trial date	11 December 2018
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To determine the within-person differences in serum phosphate after taking sevelamer at 2.4g/day and 7.2g/day compared with placebo.

Protection of trial subjects:

The trial was designed to minimise inconvenience to patients in terms of the number of visits they needed to make to the study centre and interns of managing the pill burden

Background therapy:

N/A

Evidence for comparator:

A matching placebo was used.

Actual start date of recruitment	15 February 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 72
Worldwide total number of subjects	72
EEA total number of subjects	72

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0

Adults (18-64 years)	10
From 65 to 84 years	60
85 years and over	2

Subject disposition

Recruitment

Recruitment details:

Between June 2017 and June 2018 patients were recruited from 2 UK centres in London (St Bartholomews Hospital and Guys & St Thomas's Hospital).

Pre-assignment

Screening details:

All patients had mild to moderate Aortic stenosis defined as peak velocity of trans aortic valve blood flow between 2.0 and 4.0m/s. They were not eligible if they were pregnant or breast feeding, allergic to sevelamer, had a history of hypophosphatemia, bowel obstruction, lactose intolerance, required phosphate binding drugs or other interacting

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Assessor

Blinding implementation details:

Randomised schedule produced independently of clinical investigators. Active and matching placebo packaged independently. Allocation sequence concealed from investigators and subjects and analysis's.

Arms

Are arms mutually exclusive?	No
Arm title	sevelamer

Arm description:

Sevelamer (800mg) taken with food at meal times up to a maximum of 2.4g per day for 6 weeks
Sevelamer (2.4g) taken with food at meal times up to a maximum of 7.2g per day for 6 weeks

Arm type	Active comparator
Investigational medicinal product name	Sevelamer
Investigational medicinal product code	PRD1627600-1627608
Other name	Sevelamer Carbonate
Pharmaceutical forms	Film-coated tablet and gastro-resistant granules in sachet
Routes of administration	Oral use

Dosage and administration details:

800mg tablets, one with each meal up to 2.4g per day for 6 weeks orally

Arm title	Placebo
------------------	---------

Arm description:

Matching placebo

Arm type	Placebo
Investigational medicinal product name	PLACEBO of Sevelamer carbonate 800 mg Film-coated tablets
Investigational medicinal product code	N/a
Other name	
Pharmaceutical forms	Film-coated tablet and gastro-resistant granules in sachet
Routes of administration	Oral use

Dosage and administration details:

Matching Placebo - 3 times daily with food; each regimen lasted 6 weeks

Number of subjects in period 1	sevelamer	Placebo
Started	72	72
Completed	61	61
Not completed	11	11
Too many Pills	-	4
Adverse event, non-fatal	7	7
Too many Pills	4	-

Baseline characteristics

Reporting groups

Reporting group title

Overall trial

Reporting group description: -

Reporting group values	Overall trial	Total	
Number of subjects	72	72	
Age categorical			
Units: Subjects			
In utero		0	
Preterm newborn infants (gestational age < 37 wks)		0	
Newborns (0-27 days)		0	
Infants and toddlers (28 days-23 months)		0	
Children (2-11 years)		0	
Adolescents (12-17 years)		0	
Adults (18-64 years)		0	
From 65-84 years		0	
85 years and over		0	
Age continuous			
Units: years			
median	65		
full range (min-max)	35 to 88	-	
Gender categorical			
Units: Subjects			
Female	19	19	
Male	53	53	

End points

End points reporting groups

Reporting group title	sevelamer
Reporting group description: Sevelamer (800mg) taken with food at meal times up to a maximum of 2.4g per day for 6 weeks Sevelamer (2.4g) taken with food at meal times up to a maximum of 7.2g per day for 6 weeks	
Reporting group title	Placebo
Reporting group description: Matching placebo	

Primary: Change in serum phosphate concentration

End point title	Change in serum phosphate concentration ^[1]
End point description: To determine the within-person differences in serum phosphate concentration after taking sevelamer at 2.4g/day and 7.2g/day compared with placebo.	
End point type	Primary
End point timeframe: pre and post study treatment periods	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The System does not accept the data being entered- this is blank. Full data attached in study document

End point values	sevelamer	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	61	61		
Units: mg/Dl				
number (not applicable)	61	61		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information^[1]

Timeframe for reporting adverse events:

Through our the study period

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	22.1
--------------------	------

Frequency threshold for reporting non-serious adverse events: 0 %

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.

Justification: The System does not accept the data being entered- this is blank. Full data attached in study document

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported